Sensei Biotherapeutics Announces Inclusion in Russell 2000 Index
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Sensei Biotherapeutics (Nasdaq: SNSE) has been added to the Russell 2000® Index effective March 22, 2021. The Russell 2000® Index represents the small-cap segment of the U.S. equity market and is a key benchmark for investment managers and institutional investors, with approximately $9 trillion in assets benchmarked against the Russell U.S. Indexes.
This inclusion offers Sensei Biotherapeutics enhanced visibility and potential access to a broader range of investors and index funds.
Positive
- Inclusion in the Russell 2000® Index increases visibility and attractiveness to institutional investors.
- Access to approximately $9 trillion in assets benchmarked to Russell U.S. Indexes may drive demand for shares.
Negative
- None.
Details
News Market Reaction – SNSE
The recorded move for SNSE in the trading session of this news was -2.91%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON and ROCKVILLE, Md., March 22, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced that it will be added to the Russell 2000® Index effective March 22, 2021, as part of its quarterly initial public offering (IPO) additions. The Russell 2000® Index measures the performance of the small cap segment of the U.S. equity market. Membership in the Russell 2000® provides automatic inclusion in the appropriate growth and value style indexes.
The Russell U.S. Indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately
About Sensei Biotherapeutics
Sensei Biotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company has developed a proprietary bacteriophage-based platform, ImmunoPhage™, that enables the rapid generation of immune activating therapeutic agents that fully engage the immune system. Using the ImmunoPhage™ platform, Sensei is developing a library of ImmunoPhage, called Phortress™, to target multiple tumor-associated antigens to create a personalized yet off-the-shelf cocktail approach for treating cancer patients. The platform enables efficient, scalable and cost-effective manufacturing to support all of Sensei’s clinical programs. The company’s most advanced immunotherapy, SNS-301, a first-in-class ImmunoPhage™ targeting the tumor antigen Aspartyl beta Hydroxylase (ASPH), is currently in a Phase 1/2 clinical trial in patients with advanced Squamous Cell Carcinoma of the Head and Neck. Earlier stage programs include SNS-401, an ImmunoPhage™ cocktail for the treatment of Merkel Cell Carcinoma, and SNS-VISTA, an antibody-based therapeutic targeting an immune checkpoint gene that inhibits anti-tumor immune responses called V-domain Ig suppressor of T cell activation (VISTA).
Investor Contact:
Julie Seidel
Stern Investor Relations, Inc.
212-362-1200
Media Contact:
Laura Liotta
Sam Brown, Inc.
484-580-6411
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.